DSIP is an endogenous neuropeptide involved in the regulation of deep sleep, stress reactions, and recovery processes in the body. The synthetic analog of DSIP is widely used in programs to improve sleep quality, restore the nervous system, reduce stress and support active longevity, where sleep is considered as the foundation of health and biological youth.
Delta sleep-inducing peptide (DSIP) is a naturally occurring neuropeptide consisting of nine amino acids, first isolated from rabbits in the 1970s. So named for its ability to stimulate slow-wave (delta) sleep in experimental animals, DSIP has been studied for its role in regulating sleep, stress response, and pain modulation. Despite its name, research shows that DSIP has broader functions beyond sleep induction, potentially affecting neuroendocrine regulation and immune function. It has been investigated as a potential therapeutic agent for insomnia, depression, and pain conditions. The exact physiological role of DSIP and the mechanism of its action continue to be the subject of research.
General information
| Features | Values |
|---|---|
| The peptide sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| The molecular formula | C35H48N10O15 |
| Molecular weight | 848.8 g/mol |
| CAS Number | 62568-57-4 |
| PubChem CID | 68816 |
| Synonyms | Emideltide, 62568-57-4, DELTA SLEEP INDUCING PEPTIDE, DSIP nonapeptide |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
Delta sleep-inducing peptide (DSIP) is a neuropeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), which was first isolated from the venous blood of the brain of rabbits during sleep in the 1970s.
As the name suggests, DSIP was initially identified due to its apparent ability to stimulate slow-wave (delta) sleep, which is the deepest stage of non-REM sleep. Subsequent studies have shown that its effects may be more complex and potentially go beyond sleep regulation.
DSIP has been studied for various potential physiological roles, including:
DSIP has been investigated for potential use in sleep disorders, pain management, and substance withdrawal syndromes.
DSIP and sleep regulation
DSIP is known for its ability to induce delta sleep, a type of non-REM sleep characterized by slow-wave EEG patterns.
It has been shown to promote sleep in several animal species, including rabbits, rats, mice, and humans, while its effects on REM sleep in cats vary. DSIP has been shown to affect levels of neurotransmitters, including serotonin (5-HT), glutamate, dopamine, and melatonin, which are crucial for regulating sleep. It also affects electrophysiological activity, circadian rhythms, and hormone levels, indicating its widespread effects on physiological processes.
DSIP promotes sleep in a species-specific way, having different effects on different types of sleep in different species. In clinical studies, DSIP has been shown to normalize disturbed sleep and improve wakefulness and performance while awake.
Despite the known effects, the physiological role of DSIP remains unclear, partly due to the lack of identification of its gene and receptor. It has been suggested that there are DSIP-like peptides with similar biological activity.
DSIP and anesthesia
In clinical studies, the use of DSIP resulted in a marked reduction in pain levels in patients with various pain syndromes, including migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain attacks. The peptide not only reduced the severity of pain, but also reduced the duration and frequency of pain episodes, indicating its potential as a therapeutic agent for the treatment of chronic pain.
DSIP also affects circadian rhythms related to pain perception. In studies on rats, the use of DSIP changed the circadian pain threshold, increasing it both during daylight and at night. This effect was independent of naloxone, which indicates a different mechanism from its opioid-mediated antinociceptive action.
DSIP and withdrawal symptoms
DSIP has shown promising results in the treatment of withdrawal symptoms in both alcohol-dependent and opiate-dependent individuals. In a study involving 67 patients, DSIP treatment had a positive effect on 48 of the 49 patients to be evaluated. Treatment led to an immediate and permanent disappearance of somatic symptoms, while anxiety decreased more slowly.
Another study involving 107 inpatient patients reported that DSIP treatment led to a marked and rapid improvement in clinical symptoms in 97% of opiate addicts and 87% of alcohol addicts, although anxiety decreased more slowly.
Links
1. Pollard, B., & Pomfrett, C. (2001). Delta sleep-inducing peptide.. European journal of anaesthesiology, 18 7, 419-22 . https://doi.org/10.1046/J.1365-2346.2001.00917.X.
2. Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1439536.
3. Graf, M., & Kastin, A. (1986). Delta-sleep-inducing peptide (DSIP): An update. Peptides, 7, 1165-1187. https://doi.org/10.1016/0196-9781(86)90148-8.
4. Schneider-Helmert, D., & Schoenenberger, G. (1983). Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.. Neuropsychobiology, 9 4, 197-206 . https://doi.org/10.1159/000117964.
5. Kovalzon, V., & Strekalova, T. (2006). Delta sleep‐inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97. https://doi.org/10.1111/j.1471-4159.2006.03693.x.
6. Larbig, W., Gerber, W., & Schoenenberger, G. (1987). Peptidergic Pain Reducing Effects Of The Delta-Sleep-Inducing Peptide (Dsip) In Headache And Other Pain Syndroms. Cephalalgia, 7, 46 – 48. https://doi.org/10.1177/03331024870070S614.
7. Larbig, W., Gerber, W., Kluck, M., & Schoenenberger, G. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.. European neurology, 23 5, 372-85 . https://doi.org/10.1159/000115716.
8. Yehuda, S., & Carasso, R. (1987). The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive.. The International journal of neuroscience, 37 1-2, 85-8 . https://doi.org/10.3109/00207458708991805.
9. Dick, P., Grandjean, M., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.. Neuropsychobiology, 10 4, 205-8 . https://doi.org/10.1159/000118012.
10. Dick, P., Costa, C., Fayolle, K., Grandjean, M., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates.. European neurology, 23 5, 364-71 . https://doi.org/10.1159/000115715.